It expects to complete the application by the close of Q1, 2017. On 12/4/16, Kite filed a rolling BLA application with the FDA for KTE-C19, the particular therapy that drew such rave conference call reviews from Dr. Kite is hoping for its first round of many FDA approvals to occur no later than Q4, 2017. However, even if it is only partly accurate, it should present huge opportunities for Kite's patients, its employees, and last but not least, its investors. Given medical science's successes in cancer therapies over the last recent decades, Dr. the biggest breakthroughs in cancer therapy since the introduction of combination chemotherapy more than 60 years ago. After crediting the individuals and institutions who had worked on the KTE-C19 at different stages of its development, he characterized the results as showing: In Kite's conference call introduction, Belldegrun is enthusiastic about results of Zuma I, a pivotal trial for the treatment of refractory, aggressive non-Hodgkin Lymphoma (NHL). EP Vantage recently published an article on SA providing an independent overview of the publically available Zuma I data to date. It tells an exciting story, all in the context of Kite's most advanced candidate, KTE-C19. I have just completed reading Kite's Q4, 2016 conference call transcript. I am trying to keep myself from becoming too enthused over its growing prospects. I bring this all up because I have become quite interested in Kite Pharma and its cancer therapies. I assume that they believe their statements, but also that I need to verify them carefully before I act on them. I never assume that a hyper-positive CEO is lying. It is merely to state that they need to be carefully assessed. Obviously, this is not to say such statements ought to be disregarded. It is important for investors to consider the source when a CEO talks up his company's latest achievement. He is an archetypal successful CEO in this regard. Arie Belldegrun has heaping measures of enthusiasm. Kite's CEO enthuses over "biggest breakthroughs in cancer therapy since the introduction of combination chemotherapy more than 60 years ago."ĬEO enthusiasm is critical for corporate success. All hope that Kite has truly found a silver bullet to slay not only aggressive non-Hodgkin's lymphoma (the cancer targeted in the study recently announced), but also for a wide pallet of other cancers. The clip closes with a shot of the graphic above showing Kite's logo and its ambitious slogan, "Focused on the Cure."Ĭancer patients and investors are keeping their fingers crossed. Those who lack a technical background, such as myself, can get a basic understanding of the theories underlying the technology. Kite's web site features an exceptional video clip (3:13 in length) that explains how its CAR-T therapy should work to kill cancer cells. For now, Kite Pharma ( NASDAQ: KITE) is riding high on the crest of its latest trial results for its hot CAR-T gene therapy. Once-promising medical breakthroughs often crash and burn when exposed to the infinite vagaries of human experience.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |